OUTER MEMBRANE VESICLE PRIME-PROTEIN BOOST VACCINE
The present invention provides a method of immunizing a subject against a disease caused by Neisseria meningitidis , comprising administering to the subject a primer composition comprising a meningococcal outer membrane vesicle preparation, and a booster composition comprising a meningococcal protein antigen preparation. Vaccine combinations comprising primer and booster compositions and associated uses are also provided.
1 . A method of immunizing a subject against a disease caused by Neisseria meningitidis , comprising administering to the subject a primer composition comprising a meningococcal outer membrane vesicle preparation, and a booster composition comprising a meningococcal protein antigen preparation.
2 . A method according to claim 1 , wherein the disease is meningitis, septicaemia, meningococcal arthritis or pneumonia.
3 . A method according to claim 1 , wherein the disease is caused by Neisseria meningitidis serotype A, B, C, Y or W135.
4 . A method according to claim 1 , wherein the outer membrane vesicle preparation and/or the meningococcal protein antigen preparation is derived from Neisseria meningitidis serotype B.
5 . A method according to claim 1 , wherein the meningococcal protein antigen preparation is derived from Neisseria meningitidis strain NZ981254 or H44/76.
6 . A method according to claim 1 , wherein the primer composition comprises a RIVM, VA-MENGOC-BC MeNZB or MenBvac vaccine composition.
7 . A method according to claim 1 , wherein the meningococcal protein antigen preparation comprises a meningococcal outer membrane protein preparation.
8 . A method according to claim 7 , wherein the outer membrane protein preparation comprises one or more purified proteins selected from the group consisting of: PorA, PorB, FetA, NadA, transferrin binding proteins, lactoferrin binding proteins, haem and haptoglobin receptors, complement factor H binding protein, Opa protein, NspA, Omp85, PilQ, Cu, Zn-superoxide dismutase and immunogenic fragments thereof.
9 . A method according to claim 8 , wherein the outer membrane protein preparation comprises purified PorA or an immunogenic fragment thereof.
10 . A method according to claim 1 , wherein the outer membrane protein preparation is derived from Neisseria meningitidis serotype P1.7-2.4.
11 . A method according to claim 1 , wherein the primer composition and/or the booster composition further comprises an adjuvant.
12 . A method according to claim 11 , wherein the adjuvant comprises monophosphoryl lipid A or aluminium hydroxide.
13 . A method according to claim 1 , wherein the booster composition is administered 2 weeks to 12 months after the primer composition is administered to the subject.
14 . A method of promoting an immune response in a subject against a meningococcus bacterium, comprising administering to the subject a primer composition comprising a meningococcal outer membrane vesicle preparation, and a booster composition comprising a meningococcal outer membrane protein preparation.
15 . A pharmaceutical combination comprising a primer composition comprising a meningococcal outer membrane vesicle preparation, and a separate booster composition comprising a meningococcal protein antigen preparation.
16 . (canceled)
17 . (canceled)